PRESS RELEASE published on 04/23/2024 at 18:00, 2 years 5 months ago WALLIX POURSUIT SON DEVELOPPEMENT AU ROYAUME-UNI EN PARTENARIAT AVEC PRIANTO WALLIX annonce un partenariat avec Prianto, distributeur de logiciels au Royaume-Uni, pour renforcer sa présence et sa stratégie Channel mondiale Partenariat Cybersécurité Royaume-Uni WALLIX Prianto
PRESS RELEASE published on 04/23/2024 at 18:00, 2 years 5 months ago WALLIX CONTINUES ITS DEVELOPMENT IN THE UK BY PARTNERING WITH PRIANTO WALLIX partners with Prianto, a UK software distributor, to strengthen cybersecurity solutions in the region and globally. Prianto's expertise will enhance WALLIX's Channel strategy Cybersecurity Partnership UK WALLIX Prianto
BRIEF published on 04/11/2024 at 18:05, 2 years 5 months ago WALLIX annonce une croissance continue de ses revenus récurrents pour le premier trimestre 2024 Croissance Revenus Récurrents Cybersécurité WALLIX Cyberattaques
BRIEF published on 04/11/2024 at 18:05, 2 years 5 months ago WALLIX announces continued growth in recurring revenue for the first quarter of 2024 Cybersecurity Recurring Revenue Growth Cyberattacks WALLIX
PRESS RELEASE published on 04/11/2024 at 18:00, 2 years 5 months ago Maintien d'une hypercroissance des revenus récurrents au 1er trimestre 2024 WALLIX annonce une progression de +33,6% du Revenu mensuel récurrent au 31 mars 2024, avec des revenus annuels récurrents de 20,6 M€. Confirmation d'une croissance rentable dès le second semestre 2024 Cybersécurité Croissance Rentable WALLIX Revenu Mensuel Récurrent Directive NIS 2
PRESS RELEASE published on 04/11/2024 at 18:00, 2 years 5 months ago Sustained hypergrowth in recurring business in Q1 2024 WALLIX (Euronext ALLIX) announces impressive Q1 2024 performance with 33.6% MRR growth and €7.0M turnover. Confirms profitable growth from H2 2024 amidst cybersecurity market dynamics Cybersecurity Profitable Growth Q1 2024 WALLIX Euronext ALLIX
Published on 10/05/2026 at 14:45, 2 hours 38 minutes ago NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
Published on 10/05/2026 at 14:30, 2 hours 53 minutes ago Hillcrest and Equipmake Expand Partnership Talks to Include Commercial Licensing of ZVS Technology
Published on 10/05/2026 at 14:30, 2 hours 53 minutes ago Solitario CEO to Present at John Tumazos Very Independent Research, LLC
Published on 10/05/2026 at 14:00, 3 hours 23 minutes ago Tectonic Metals Appoints Eduard Epshtein as CFO, Bolstering Executive Team for Next Stage of Growth
Published on 10/05/2026 at 14:00, 3 hours 23 minutes ago GameSquare to Present at Upcoming Investor Conferences
Published on 10/05/2026 at 17:07, 15 minutes ago Amprion successfully issues more green bonds worth EUR 1.5 billion
Published on 10/05/2026 at 15:50, 1 hour 33 minutes ago EpiSign and Geneyx Announce Partnership to Integrate Genomic and Epigenomic Analysis for Rare Disease
Published on 10/05/2026 at 15:49, 1 hour 33 minutes ago Form 8.3 - The Vanguard Group, Inc.: Senior PLC
Published on 10/05/2026 at 15:47, 1 hour 36 minutes ago BROADPEAK SA: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 30.09.26.
Published on 10/05/2026 at 15:43, 1 hour 40 minutes ago Form 8.3 - The Vanguard Group, Inc.: easyJet PLC
Published on 10/05/2026 at 16:21, 1 hour 1 minute ago Guillemot Corporation S.A. | Weekly report share buyback from September 28 to October 2, 2026
Published on 10/05/2026 at 16:21, 1 hour 1 minute ago Guillemot Corporation S.A. | Déclaration hebdomadaire des transactions sur actions propres du 28 septembre au 2 octobre 2026
Published on 10/05/2026 at 15:58, 1 hour 25 minutes ago Informations relatives au nombre total de droits de vote et d’actions
